

9th Annual Innovative Approaches to Brain Tumor Management Hybrid Course

Friday, February 9, 2024 AGENDA

7:30 a.m. Registration & Breakfast

7:55 a.m. Welcome & Announcements

Zachary N. Litvack, M.D., Charles Cobbs, M.D. & Alipi Bonm, M.D., Ph.D.

8 a.m. Clinical Trial with Pembrolizumab in Relapsed GBM Patients

Robert Prins, Ph.D.

Objectives:

- Identify the rationale for neoadjuvant treatment with immune checkpoint blockade in recurrent GBM patients
- Illustrate pharmacodynamic biomarkers for neoadjuvant immune checkpoint blockade that correlate with survival

8:15 a.m. Q&A

8:20 a.m. Oncolytic Immuoactivation Clinical Trials for GBM

Nino Chiocca, M.D.

Objectives:

- Identify basic concepts of oncolytic viral therapy
- Illustrate the role of viral gene delivery in immune activation

8:35 a.m. Q&A

8:40 a.m. DNA Methylation Profiling as a Clinical Diagnostic Tool for CNS Tumors

PJ Cimino, M.D., Ph.D.

Objectives:

- Illustrate the utility of DNA methylation profiling in CNS tumor diagnosis
- Explain the limitations of potential pitfalls of DNA methylation profiling

8:55 a.m. Q&A

9 a.m. A Phase I Clinical Trial of Personalized High Throughput Drug Screening for Up

Front Treatment of Glioblastoma

Parvi Hothi, Ph.D.

Objectives:

- Identify high throughput drug screening
- Describe how cancer stem cells are good targets in GBM

9:15 a.m. Q&A

9:20 a.m. The Roles of Social Worker in Management of Glioblastoma Patient Care

Brenda Autobee-Bigalk, MSW, LICSW

Objectives:

- Demonstrate key roles for social workers in GBM care
- Identify how family dynamics impact GBM patients

9:35 a.m. Q&A

9:40 a.m. Human endogenous retrovirus K contributes to a stem cell niche in glioblastoma

Ashish H. Shah, M.D.

Objectives:

- Describe what HERV's are
- Illustrate implications of HERV-K expression in GBM

9:55 a.m. Q&A

10 a.m. Breaks & Exhibits (not for CME credit)

10:10 a.m. Glioblastoma Brain Slice Culture and Potential Role in Identifying Glioblastoma Immune Activating Molecules

Charles Cobbs, M.D.

Objectives:

- Describe the role of a GBM slice culture in immunotherapy
- Describe key concepts in making cold tumors hot

10:25 a.m. Q&A

10:30 a.m. "Imaging Endpoint Strategies for Early & Later Stage Clinical Trials in Recurrent GBM"

Benjamin Ellingson, Ph.D.

Objectives:

- Describe key imaging characteristics of GBM progression
- Illustrate unique imaging aspects of GBM in clinical trials

10:45 a.m. Q&A

10:50 a.m. Potential Role of CRISPR for Treating Glioblastoma

John Liu, M.D., Ph.D.

Objectives:

- Identify key genes involved in GBM progression
- Describe how CRISPR can inactivate tumor driven genes

11:05 a.m. Q&A

11:10 a.m. Extracellular Vesicles for Delivery of mRNA for Glioblastoma Treatment

Betty Kim, M.D., Ph.D., FRCSC, FAANS

Objectives:

- Describe EV as a delivery system
- Illustrate the potential of mRNA therapy for brain tumors

11:45 a.m. Q&A

11:50 a.m. Metabolic Imaging of Brain Tumors

Susan Chang, M.D.

Objectives:

- Illustrate how key metabolic pathways of brain tumors can drive tumor biology
- Describe imaging techniques in brain tumor management

12:05 a.m. Q&A

12:10 p.m. Lunch Break & Exhibits (not for CME credit)

12:40 p.m. Augmented Reality in Neuro-Oncology (not for CME credit)

Stephen Monteith, M.D.

12:45 p.m. Q&A

12:50 p.m. Update on Endoscopic Skull Base (not for CME credit)

Alon Orlev, M.D.

1:05 p.m. Q&A

1:10 p.m. Breaks & Exhibits (not for CME credit)

1:40 p.m. Preclinical Modeling for Improved Drug Delivery & Immunotherapeutic

Approaches to Glioblastoma

Sean Lawler, Ph.D.

Objectives:

- Explain pre-clinical modeling for drug delivery in GBM
- Illustrate immunotherapeutic approaches to GBM

1:55 p.m. Q&A

2:00 p.m. "Living Drugs" - Changing the Way We Treat Patients with Brain Cancer

Rajiv Khanna, M.D.

Objectives:

- Describe T-cell targets for GBM
- Illustrate how CMV targeting can impact GBM

2:15 p.m. Q&A

2:20 p.m. "Molecular Targeted Therapy for Glioma"

Alipi Bonm, M.D., Ph.D.

Objectives:

- Describe therapies for targeted molecular glioma
- Illustrate therapy types to treat molecular glioma

2:35 p.m. Q&A

2:40 p.m. "A Novel Mechanism of T Cell Antitumor Immunity"

Peter Fecci, M.D., Ph.D.

Objectives:

- Identify the traditional role of MHC in T cell activation and target killing
- Illustrate the role of the NKG2D-NKG2DL axis in mediating a novel mechanism of T cell killing
- 2:55 p.m. Q&A
- 3:00 p.m. Adjourn

ESTEEMED FACULTY

Charles Cobbs, M.D. Course Co-Chair

Director, Ben & Catherine Ivy Center Swedish Neuroscience Institute Seattle, Washington

Zachary N. Litvack, M.D., FAANS, FACS Course Co-Chair

Director, Skull Base & Minimally Invasive
Neurosurgery
Swedish Neuroscience Institute
Seattle, Washington

Alipi Bonm, M.D. Course Co-Chair

Neuro-oncologist Ben & Catherine Ivy Center Seattle, Washington

Brenda Autobee-Bigalk, MSW, LICSW

Medical Social Worker Ben & Catherine Ivy Center Swedish Neuroscience Institute Seattle, Washington

Nino Chiocca, M.D., Ph.D.

Co-Director, Institute for the Neurosciences, Brigham And Women's Hospital Surgical Director, Center for Neuro-Oncology Dana-Farber Cancer Institute Brigham & Women's Hospital Boston, Massachusetts

Benjamin Ellingson, Ph.D.

Professor & Director of MRI Research, Director, UCLA
Brain Tumor Imaging Laboratory, Departments of
Radiology, Bioengineering, Psychiatry, and
Neurosurgery David Geffen School of Medicine
UCLA Brain Tumor Imaging Laboratory
Los Angeles, California

Parvinder Hothi, Ph.D.

Head Lab Scientist
Ben & Catherine Ivy Center
Swedish Neuroscience Institute
Seattle, Washington

Susan Chang, M.D.

Professor, Neurological Surgery UCSF Weill Institute for Neurosciences San Francisco, California

P.J. Cimino, M.D., Ph.D.

Assistant Research Physician
Head, Neuropathology Unit, Surgical Neurology Branch,
NINDS
National Institute of Neurological Disorders and Stroke
Bethesda, Maryland

Peter Fecci, M.D., Ph.D.

Director of Brain Tumor Immunotherapy Program & Center for Brain & Spine Metastasis

Duke Cancer Center Brain Tumor Clinic

Duke University

Raleigh, North Carolina

Rajiv Khanna, Ph.D.

Professor, Senior Scientist, Deputy Coordinator of Immunology Department QIMR Berghofer Medical Research Institute Brisbane, Australia

Betty Kim, M.D., Ph.D., FRCSC, FAANS

Professor, Department of Neurosurgery, Division
Surgery
MD Anderson Cancer Center
Houston, Texas

John Liu, M.D., Ph.D.

Resident Physician in Radiation Oncology UCSF Brain Tumor Center San Francisco, California

Alon Orlev, M.D. (virtual)

Neurosurgeon Rabin Medical Center Israel

Sean Lawler, Ph.D.

Associate Professor Brown University Providence, Rohde Island

Stephen Monteith, M.D.

Neurosurgeon Swedish Neuroscience Institute Seattle, Washington

Robert Prins, M.D.

Tumor Immunologist & Professor David Geffen School of Medicine at UCLA Los Angeles, California

Ashish H. Shaw, M.D.

Assistant Professor
Director of Clinical Trials and Translational Research
Principal Investigator-Section of Virology and Immunotherapy
University of Miami Brain Tumor Initiative
Miami, Florida